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Objective: Describe the impact of Medical Nutrition Therapy on health parameters of
newly diagnosed patients with pre-diabetes in a rural Nebraska primary care clinic.
Background: Lifestyle interventions, including weight loss, exercise and diet, have a
significant impact on diabetes prevention. Medical Nutrition Therapy (MNT) provided
by a Registered Dietitian Nutritionist (RDN) is an essential part of any intervention
approach. Several visits with an RDN have shown effective results. However, multiple
visits become prohibitive, especially in rural areas, due to inaccessibility and cost when
not covered by insurance.
Methods: This 2010 retrospective study of electronic health records examined newly
diagnosed pre-diabetes patients who received (n=20, mean age 61, 85% female) or did
not receive MNT (NMNT) (n=22, mean age 63, 82% female) in a 12 month time period
after diagnosis. Health parameters (weight, Body Mass Index (BMI), fasting blood
glucose (FBG), Hemoglobin A1C (A1C), lipids, blood pressure) were collected at
baseline and repeat measurements were recorded from health records as close to one-year
post diagnosis as available. Data were analyzed using Chi Square and Mixed Procedure.
Results: After adjusting for medications, greater weight loss and BMI change were
observed and expected to continue in those who received MNT, although the difference
was not significant. (P >0.05). The MNT group had a significant predicted decrease from

	
  
	
  

baseline to time 2 in FBG (P=0.036), in A1C (P=0.05) and an increase of nearly 4 mg/dl
(P=0.028) in HDL cholesterol (HDL-C). The NMNT group experienced approximately a
50 mg/dl decrease in triglyceride levels (P=0.05) but also had unexpected medication
starts or dosage increases (P=0.01). Other lipid and blood pressure changes were not
significant.
Conclusions: Patients with pre-diabetes receiving limited MNT provided by a RDN had
positive changes in body weight and BMI, a lowering of FBG and A1C, and improved
HDL-C after a year post diagnosis, and less medication starts or changes than patients
without MNT.
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CHAPTER I
INTRODUCTION
As early as the 1920’s, Dr. Elliott Joslin spoke not only of the need for treatment
of diabetes but also prevention.1 Today more than twenty six million adults in the United
States have diabetes. Another 79 million, or a third of the adult population, are estimated
to have pre-diabetes according to a 2011 Centers for Disease Control and Prevention
report.2 This mirrors the obesity and overweight percentage rates which have soared to
97 million adults, a 48% increase over the past decade.3,4 Of even greater concern is that
obesity rates in children and adolescents have more than tripled in the past 30 years
affecting their risk of developing diabetes.5,6
A combination of genetic and lifestyle factors effect the development of type 2
diabetes. Insulin resistance increase and beta cell loss during pre-diabetes years
significantly impact the body’s insulin needs and alter normal physiology leading to
progression of diabetes. Higher body weights are associated with an increase in all cause
morbidity and mortality and it is a preventable contributor to diseases such as type 2
diabetes. Lifestyle changes can improve insulin resistance, help preserve beta cell
function, and slow or halt the development of type 2 diabetes.7 Diabetes has reached
epidemic levels and is found in almost every population worldwide. With increasing
obesity rates and lack of physical activity, type 2 diabetes has become one of the leading
chronic diseases surpassing the prediction rates for diabetes from 20 years ago.3 The
growing diabetes epidemic has had a devastating impact on quality of life and overall
health-care costs. The United Kingdom Prospective Diabetes Study (UKPDS)
investigated the effect of intensive blood glucose control versus conventional treatment in
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patients with type 2 diabetes over approximately 10 years. Researchers demonstrated a
direct relationship between the risk of diabetic complications and glycemia over time.
Each 1% absolute reduction in mean Hemoglobin A1C (A1C) levels was associated with
a 37% decrease in the risk of microvascular complications and a 21% reduction in the
risk of any diabetes-related complication or death.8 Diabetes is the leading cause of
kidney failure, non-traumatic lower-limb amputations, blindness and heart attack and
stroke in adults in the United States so any improvement in A1C levels is likely to reduce
these risks.2 The consequences of diabetes are significant so there is urgency in finding
ways to slow or halt the development of the disease.
Pre-diabetes raises short-term absolute risk of type 2 diabetes five- to six fold.16
Pre-diabetes is recognized in individuals whose glucose levels, although not meeting
criteria for diabetes, are too high to be considered normal. Pre-diabetes is defined by the
American Diabetes Association as an impaired fasting glucose (IFG) (fasting plasma
glucose (FPG) levels 100 mg/dl to 125 mg/dL) or impaired glucose tolerance (IGT) (2-h
values in the oral glucose tolerance test (OGTT) of 140 mg/dL to 199 mg/dL). (Appendix
2) In 2010, statistics revealed that 10.9 million adults aged 65 or older had diabetes.1
Type 2 diabetes (Appendix 3), once called adult-onset diabetes, was considered a disease
of later life. Though it is more prevalent in age 65 and older, type 2 diabetes is now
affecting people of all ages in staggering numbers. Evidence shows that those with prediabetes are likely to develop type 2 diabetes within 10 years unless steps are taken to
prevent or delay it.9 The Diabetes Prevention Program (DPP) provided conclusive
evidence that lifestyle intervention in overweight persons with pre-diabetes can delay or
prevent the progression to type 2 diabetes. Even a modest weight loss through dietary
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changes and increased physical activity had a significant impact on their chances of
developing diabetes. Lifestyle interventions included diet and exercise changes through
counseling and behavior modification. Poor nutrition appears to be a major contributor to
this problem and medical nutrition therapy (MNT) for people with pre-diabetes appears
to be one of the best approaches to prevention. MNT provided by a registered dietitian
nutritionist (RDN) has been proven to be an important aspect of treatment in delaying or
preventing the onset of diabetes.
Results from large randomized controlled trials (RCT) reported positive outcomes
when subjects received numerous sessions with a RDN over an extended period of time.
However, little is known about the impact of a limited number of MNT visits on
outcomes in individuals with pre-diabetes. Patients in rural areas may have few resources
and limited accessibility to diabetes programs and/or a RDN. MNT for pre-diabetes is
typically not a covered service by health insurance, Medicare and Medicaid. Costs, travel,
or knowledge of available resources may also be problems. Because of these issues,
patients who choose to address their health issues often see a RDN for only one MNT
visit. Patients lacking follow-up MNT support can have diminished outcomes over time,
however, based on research findings.
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CHAPTER II
LITERATURE REVIEW

Factors in the development of type 2 diabetes
Genetics- The development of diabetes is clearly linked to a family history of
diabetes. The genetic components of insulin resistance and impaired insulin secretion,
along with aging, involve multiple genes that are impacted more or less by environmental
factors that trigger changes. Insulin resistance begins long before the onset of diabetes
and is the underlying condition of insufficient insulin action at the cells receptor sites in
response to elevated glucose levels. Pancreatic beta cell function is also found to be about
50% of normal at diagnosis of type 2 diabetes with changes beginning as soon as
approximately 10 years earlier. Glucolipotoxicity and inflammatory mediators are factors
that affect insulin secretion and impair insulin signaling. High triglycerides, depressed
high density lipoprotein cholesterol (HDL-C), elevated blood pressure (BP), elevated
fasting blood glucose (FBG) and abdominal obesity are all signs of insulin resistance or,
metabolic syndrome, (Appendix 4) which often surface in pre-diabetes years. Impaired
insulin secretion also occurs early leading to postprandial hyperglycemia and progresses
due to pancreatic beta cell loss over time. With sufficient beta cell loss, diabetes develops.
Aging is also associated with insulin resistance due to changes in body composition,
namely body fat accumulation in the abdominal region and accompanying muscle mass
loss.10 Thus, the development of insulin resistance and type 2 diabetes is multifactorial.
However, insulin sensitivity can be impacted by diet, weight loss, exercise or a
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combination of lifestyle changes that lead to an improvement in insulin response and
blood glucose levels.
Diet- The wide spread epidemic of diabetes appears to be linked to changes in
dietary patterns and poor nutritional intake across the globe. A study conducted at the
India Institute of Diabetes at Mumbai identified nutritional problems in their culture that
has accelerated the rate of conversion of pre-diabetes states to diabetes. They concluded
that diets high in fat, and insufficient in healthy fatty acids, Vitamin D and antioxidants
are the main problems and correlate this with a highly refined, processed, and
preservative filled diet.11 It is known that a diet high in fat, independent of body weight,
has an impact on insulin sensitivity. However, the type of fat also matters.
Epidemiological studies results found an association between higher fasting insulin and
glucose levels and more pronounced glucose intolerance with a high saturated fat diet.
Findings from long-term clinical trials support a diet that is rich in whole grains, fruits
and vegetables, and other high fiber carbohydrates. Low-fat dairy products, moderate
alcohol consumption, and reasonable coffee or tea intake may be part of a beneficial diet
plan. Overall a diet that is low in total fat (<30% of energy), especially animal fat and
saturated fat, and simple sugars appear to be best in prevention of diabetes.12 A
Mediterranean-style diet with foods of low-glycemic load may also affect the metabolic
changes that occur with insulin resistance and the metabolic syndrome.13 A recent review
of prospective cohort studies showed consistent and significant lowering in the incidence
of type 2 diabetes in individuals who consumed a lower-glycemic load diet.14 Kahleova
and colleagues found that a calorie-restricted vegetarian diet improved insulin sensitivity
compared to a conventional diet over a 6 month period. They concluded that the effects
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might in part be explained by weight loss, especially visceral fat loss, which improved
insulin sensitivity.15 Weight loss through dietary calorie restriction and nutrient intake
change are supported in several studies as a way of preventing diabetes.
Obesity- The association of obesity (Appendix 5 and 6) with increased risk of
developing insulin resistance and type 2 diabetes is shown in many studies. Insulin
resistance worsens in obesity due to metabolic changes and release of hormones,
adipocytokines, non-esterified free fatty acids, and other substances from fat cells.
Pancreatic beta cells increase insulin production to normalize glucose levels, but
eventually due to beta cell loss glucose levels remain elevated. Researchers have shown
that the development of type 2 diabetes can be delayed or possibly prevented in obese
individuals if weight loss is achieved.16 Jazet and colleagues showed that a loss of 50% of
excess weight normalized endogenous glucose production and improved insulin
sensitivity. The preservation of beta cells in the pancreas and the capacity to secrete
adequate amounts of insulin was shown to be important in predicting outcomes of diet on
glucose lowering in obese patients.17 A review of studies by Norris and colleagues looked
at the effectiveness of weight-loss and weight-control interventions on adults with prediabetes in prevention of diabetes. They concluded that weight-loss strategies that
incorporate dietary, physical activity, or behavioral interventions producing significant
weight improvements resulted in a significant reduction in diabetes occurrence in people
with pre-diabetes.18
Physical inactivity- The rise in obesity in recent decades is attributed in part to
the decrease in physical activity. Both cross-sectional and longitudinal study researchers
have found physical inactivity to be an independent predictor of type 2 diabetes. The
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more physically active subjects had lower incidence of diabetes. Populations who have
migrated to westernized countries have an increased risk of type 2 diabetes due to
adopting more sedentary lifestyles compared to natives of their country of origin.19
Activity Guidelines for Americans were published by the US Department of Health and
Human Services in 2008 to give direction for weekly activity goals. (Appendix 7)

Preventing diabetes
Lifestyle intervention studies - Achieving and maintaining a healthy weight
through diet and physical activity are interventions used most often in diabetes prevention
trials in individuals at high risk for developing diabetes. Yoon and colleagues completed
a 2013 meta-analysis of randomized controlled trials. They determined there is
substantial evidence that the development of type 2 diabetes can be prevented or delayed
through lifestyle intervention in most high-risk individuals.20 One of the earliest lifestyle
intervention studies was done in Malmö, Sweden. Eriksson and Lindgärde took subjects
with early-stage type 2 diabetes and IGT and prospectively studied long-term lifestyle
intervention effect on development of type 2 diabetes. After 6 years they found that
greater than 50% of subjects with IGT at baseline, who made dietary changes and
increased their physical activity level, had normalized glucose tolerance. They also
found that more than 50% of those with diabetes were in remission.21 Their results were
supported by large follow-up randomized controlled trials in the United States, Finland,
China, Japan, and in native Asian Indians.22-30 The Da Qing Impaired Glucose Tolerance
(IGT) and Diabetes Study, the Finnish Diabetes Prevention Study (DPS) and the US
Diabetes Prevention Program (DPP) findings confirmed lifestyle intervention makes a
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difference.22-24, 27-30 The DPS and DPP were the first and the largest randomized
controlled trials to date, respectively, to study the efficacy of an intensive diet-exercise
program in preventing or delaying type 2 diabetes in individuals with IGT. The DPS
lifestyle intervention provided individualized counseling focused on reducing weight and
fat intake and increasing fiber intake and exercise. The DPP worked to achieve 5-7 %
weight reduction from initial body weight through a healthy low-calorie, low-fat diet and
some form of moderate physical activity for at least 150 minutes per week. All of these
studies provided evidence that in obese subjects with impaired glucose tolerance, lifestyle
changes had a significant impact in preventing diabetes through healthy diet, weight loss
and physical activity. Other large population groups were studied in Japan and in Asian
Indians, and smaller groups in Sweden and the Netherlands. Although the groups
differed in some manner, the initial results were all similar. Lifestyle intervention had an
effect on incidence of diabetes development.25-26
Physical activity and weight loss effect- Physical activity and weight loss have
been shown to be effective in the prevention of diabetes. The improvement in Malmö
subjects’ glucose tolerance was correlated to weight reduction and increased physical
fitness that contributed to decreased mortality in the treatment groups.21 Conclusions of a
four-year follow-up of DPP revealed that an increase in physical activity sustained weight
loss and helped reduce risks for those who did not lose weight. They also identified
improved lipid parameters, reduced hypertension and improved fasting glucose and
glucose tolerance with lifestyle modification.24 The Da Qing IGT and Diabetes Study
found similar results after active interventions ended in Chinese subjects after 6 years.
The diet intervention alone was associated with a 31% reduction in the risk of developing
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type 2 diabetes while the exercise intervention alone showed a 42% reduction similar to
diet and exercise combined.22 The male subjects in Japan studied by Kosaka and
colleagues had repeated dietary and lifestyle instruction which led to a 67% reduction in
risk of diabetes over 4 years compared to controls who were only advised initially to
maintain a normal body mass index by diet and exercise. They concluded that diabetes
incidence was positively correlated with body weight change.25 This was supportive of
follow-up analyses of the DPS and the DPP suggesting weight loss as the factor that
reduced diabetes incidence. During a 16-year follow-up of 85,000 females in the Nurses’
Health Study, excess body fat was identified as the single most important determinant of
type 2 diabetes. The study supported weight control through diet and exercise as the
most effective way to reduce risk of developing type 2 diabetes by as much as 83%.31 A
2005 review by Norris and colleagues concluded that dietary, physical activity or
behavioral interventions significantly affected the weight of persons with pre-diabetes.
Although they found weight loss amounts to be statistically insignificant, studies
demonstrated weight loss even at modest amounts led to improvements in A1C, blood
pressure and triglycerides.18 Their findings may be explained by Perreault and colleagues
and the DPP Research Group who looked at regression from pre-diabetes to normal
glucose regulation. They concluded normal glucose regulation is key to prevention of
diabetes, and although aging can affect this process, normal glucose regulation may be
attained through weight loss, healthy eating and exercise.32
Medication effect- Several studies compared lifestyle intervention to medication
intervention in the prevention of diabetes. Progression of IGT to type 2 diabetes is high
in native Asian Indians, so Ramachandran and colleagues tested whether the progression
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to diabetes in this population could be altered by lifestyle modification, medication
intervention (metformin) or both. They found that both lifestyle modification and
metformin significantly reduced the incidence of diabetes, but there was no further
benefit when the two were combined.26 The DPP also compared lifestyle intervention to
medication intervention (metformin) and found that although both had positive effects on
prevention of type 2 diabetes, the lifestyle intervention was more effective, especially in
older adults.24 Three medication intervention studies, The Xenical in the Prevention of
Diabetes in Obese Subjects (XENDOS (orlistat)), The Troglitazone in Prevention of
Diabetes (TRIPOD (troglitizone)), and The Study to Prevent Non-Insulin-Dependent
Diabetes (STOP-NIDDM (acarbose)), all demonstrated reduced risk in the progression to
diabetes, and the medications may become important adjuncts to lifestyle intervention in
the future.18
Long-term effects of lifestyle change - Findings of the Finnish Diabetes
Prevention Study (DPS) showed that even after individual lifestyle counseling had
stopped, people at high risk of developing type 2 diabetes continued to sustain lifestyle
change that reduced the incidence of diabetes. Similar results were found in the DPP
groups with diet and exercise intervention reducing the incidence of type 2 diabetes by
more than half compared to the control group.23, 24 A 4 year follow-up of DPS by
Lindström, et al, reported the impact of lifestyle change continued to have an impact on
diabetes incidence.27 The Da Qing results extended to 6 years and showed significant
results continued.22 At 12-years, the Malmö intervention group had the same mortality
rate as normal glucose tolerant control subjects and half the mortality rate of impaired
glucose tolerant control subjects. After 13 years, DPS participants had relative risk
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reduction of 38%28 similar to findings in the Da Qing Diabetes Prevention Study over 20
years (43%)29 and the DPP Outcomes Study over 10 years.30 The Swedish study showed
lifestyle intervention had a significant effect until the third follow-up year when the effect
disappeared. Ultimately, all studies found lifestyle intervention impacted type 2 diabetes
incidence but results had a diminished effect over time.32
Implementation of interventions and the role of the RDN. The American
Diabetes Association’s (ADA) 2013 Clinical Practice Recommendations state that
“patients with IGT, IFG, or an A1C of 5.7-6.4% (Appendix 8) should be referred to an
effective ongoing support program targeting weight loss of 7% of body weight and
increasing physical activity to at least 150 minutes/week of moderate activity such as
walking.” The Prevention/Delay of Type 2 Diabetes section (ADA 2013) goes on to state,
“follow-up counseling appears to be important for success.” Their general
recommendations are “individuals who have pre-diabetes or diabetes should receive
individualized MNT as needed to achieve treatment goals, preferably provided by a
registered dietitian familiar with the components of diabetes MNT.”33 Large RCT’s
support lifestyle intervention, that is provided for a limited time, as an approach that
produces long-term benefits in reducing the risk of type 2 diabetes in high-risk
individuals. Though these studies have shown the efficacy of lifestyle intervention, one
question remains a challenge. How can the same interventions be implemented in
primary healthcare settings and who should provide it? Multiple studies have been
designed to translate the DPP approach into routine clinical settings. Sakane and
colleagues attempted to implement lifestyle interventions through health checkups in
communities and worksites with public health nurses and determined after 3 years that
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existing healthcare resources were beneficial in preventing diabetes in high-risk subjects.
Subjects attended and learned with positive outcomes when information was provided in
places that were in close proximity and convenient in their own medical clinic.34 The
Active Prevention in High-Risk Individuals of Diabetes Type 2 in and Around Eindhoven
(APHRODITE) study utilized nurse practitioners in Dutch primary care clinics to provide
lifestyle counseling with goals of ≥5% weight reduction if overweight; physical activity
for at least 30 minutes 5 days weekly; intake of dietary fat <30% of total energy intake;
intake of saturated fat <10% of total energy intake; and intake of dietary fiber of at least
3.4 g per mega joule. (14g per 1000 Kcal) Four one-hour group meetings with a dietitian
were provided during the first 5 weeks of an 18-month study. The cost of intervention
was concluded to be suitable for real-life settings but the effect was modest compared to
usual care, which they attributed in part to health-care providers (HCP) not being able to
convince patients of the importance of weight loss or weight maintenance.35 The DEPLAN Study reported similar results in the first community-based lifestyle intervention
program in Greece. Once high risk participants were identified, they participated in a
one-year intervention program meeting bi-monthly with a dietitian. They found that
although weight loss was moderate (1.0 ± 4.7 kg), glucose levels improved. They
concluded that the DPP and DPS intervention strategies, though effective, were not
practical in most communities or primary care practices. They suggested that group
sessions with a dietitian, at a work site or near participant’s residencies, could be a
practical and feasible approach to lifestyle intervention for people with pre-diabetes.36
Other studies, including The Healthy Living Partnership to Prevent Diabetes by Katula
and colleagues found they could make modifications to the original DPP guidelines
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configuring it to meet their community needs and have successful outcomes.37 A metaanalysis conducted by Cardona-Morrell, and colleagues concluded that lifestyle
interventions for high-risk individuals are feasible when delivered by healthcare
providers in regular clinical settings but show limitations in clinical benefit one year after
the intervention concludes.38 Concern was also raised by Yoon and colleagues in a recent
review of the literature as to whether the interventions from evidenced-based trials could
be replicated in community settings. Further studies, such as The Good Aging in Lahti
Region (GOAL) Lifestyle Implementation Trial was designed to test the effectiveness of
risk reduction objectives derived from the DPS in primary health care settings. Their
goal was to determine if comparable results of the prevention trials could be achieved in
real world conditions in the existing health-care system. Although subjects achieved
dietary fiber and fat goals, only 12% of participants met weight loss goals of at least 5%.
Public health nurses and physiotherapists conducted the groups, but the authors attributed
the favorable nutrition outcomes to investment in a program dietitian. They also
concluded that group-based lifestyle counseling is feasible in real-life settings for
evidence-based diabetes prevention.39
Does a nutrition professional providing medical nutrition therapy affect
outcomes? Wolf and colleagues conducted a one year randomized controlled trial with
obese women with Type 2 diabetes. The intervention group received individual and
group education and support from registered dietitians while the control group was
provided with educational materials only. They found that the RDs’ intervention group
had significantly greater weight loss, waist circumference change and improved health
outcomes. There was also an improvement in A1C level and decreased use of diabetes
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prescription medications compared to control group participants.40 Kramer and
colleagues studied the effect of a community-based diabetes prevention program
delivered by diabetes educators (registered dietitians and nurses). Mean overall weight
loss for participants was greater than 5% with significant decreases also noted in fasting
plasma glucose, low-density lipoprotein cholesterol, triglycerides, and blood pressure
after a 12 session DPP- modeled group program. The results were similar to other DPP
translation efforts.41 Multiple clinical trials and outcome studies have reported decreases
in A1C with MNT intervention, including a registered dietitian-led diabetes management
program in primary care clinics in Taiwan. Huang and colleagues concluded that on-site
registered dietitians significantly improved the glycemic control of type 2 diabetic
patients.42 Sustained A1C improvements were also found at one year by Johnson and
Thomas. A registered dietitian provided MNT to adult patients who had a 20% reduction
in their A1C level compared to 2% reduction in subjects who had not received MNT
intervention.43 In 2002, Pastors and colleagues concluded that evidence-based research
strongly suggested that MNT provided by a registered dietitian who is experienced in the
management of diabetes is clinically effective and that MNT does make a difference.44
Recently, Delahanty studied the role of registered dietitians in improving diabetes-related
health outcomes in important landmark lifestyle intervention studies. She determined
that the evidence clearly demonstrated RDs have an increasingly important role, serving
also as a lifestyle coach and case manager, regarding early MNT intervention in obesity,
pre-diabetes and diabetes. She found that RDs played a key role in the DDP findings
where lifestyle intervention was more effective than medication in the prevention of type
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2 diabetes. She also concluded that building long-term relationships with clients help
sustain lifestyle habits that translate into health benefits and cost savings over time.45
Cost savings interventions- As the number of people with diabetes grows so
does the costs associated with the disease. Using 2007 U.S. Census and Federal
epidemiologic data, researchers Dall and Zhang and colleagues estimated that the average
cost of national medical care for those with pre-diabetes was $25 billion.46-47 While the
impact of pre-diabetes costs is significant, an even greater concern is the cost associated
with Type 2 diabetes exceeding an estimated $192 billion.2 The American Diabetes
Association’s Standards of Medical Care in Diabetes-2013 recommend, “Because MNT
can result in cost-savings and improved outcomes, MNT should be adequately covered
by insurance and other payers.”33 A study conducted by Francis and colleagues compared
healthcare utilization and costs of patients with or without hypertension and pre-diabetes.
Of the patients that met study criteria, approximately a third progressed to diabetes within
the data collection time. They concluded that over a 3-year follow-up, those with prediabetes who progressed to type 2 diabetes, had significantly higher healthcare utilization
and overall costs increased by almost $1500 in 1 year compared with patients who did
not progress to diabetes.48
Attention has shifted to primary prevention of type 2 diabetes because of the
escalating costs associated with diabetes treatment. But is the cost of prevention through
lifestyle intervention more reasonable? Eddy and colleagues, using a validated model,
evaluated the cost effectiveness of the DPP. The results of analysis revealed that over 30
years there was an 11% reduction of high-risk persons getting diabetes after the DPP
lifestyle program. Cost was estimated at $143,000 for lifetime, approximately a third less
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than starting intervention at diabetes diagnosis. They concluded that lifestyle
modification should be recommended to all high-risk people to reduce the morbidity and
mortality of diabetes. However, they also determined that the DPP program might be too
expensive for implementation on a comprehensive basis.49 Because researchers in
Canada also recognized diabetes interventions could be expensive, they compared the
cost and health outcomes of an intensive lifestyle modification program, metformin or no
intervention to prevent progression to diabetes in IGT individuals. Their results
suggested that although intensive lifestyle modification strategies were not the cheapest
intervention in the treatment of pre-diabetes, the greatest health benefits were realized at
reasonable costs and may generate savings over time.50
Registered dietitian nutritionist involvement in lifestyle intervention strategies is
important and has been proven to be cost effective. The cost savings of the Improving
Control with Activity and Nutrition (ICAN) program supported incorporating lifestyle
interventions led by a registered dietitian. The savings for ICAN participants were
significant in inpatient admissions and also suggested possible savings in obese type 2
diabetes patients where complications often require expensive treatments.51 Franz and
colleagues also looked at the cost and overall effectiveness of medical nutrition therapy
provided by registered dietitian. They concluded that substantial metabolic control could
be achieved through nutrition intervention using practice guidelines with a reasonable
cost.52 Sikand and colleagues confirmed that MNT could be a cost effective intervention.
Dietitian intervention of an average of 3 one-hour sessions over 8 weeks led to not only
improved clinical parameters, but also a realized cost savings of $3.03 in medication
savings (statins) for every dollar spent on MNT. They cited statistically significant
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reductions in hospital admissions and physician office visits for patients with diabetes
and cardiovascular disease that have received MNT.53 However, despite the evidence,
Medicare continues to deny payment for physician-referred MNT for pre-diabetes or
cardiovascular disease. The chief medical officer of Blue Cross & Blue Shield of North
Carolina, and other well-respected professionals recently published a peer-reviewed
article on the value of MNT in weight management. They retrospectively evaluated the
cost of and health benefits attributed to MNT for overweight or obese adult managed care
members who participated in a weight management program. They found that
individuals who received MNT were about twice as likely as matched controls to achieve
a clinically significant reduction in weight and cost $0.03 per member per month.54
If lifestyle interventions remain successful over time, significant cost savings and
improved health outcomes could be achieved. Many organizations, agencies, groups and
individuals are working on ways to prevent diabetes. National efforts along with state
and local programs are trying to address the epidemic through lifestyle intervention
programming. The federal government, through the Centers for Disease Control and
Prevention (CDC), allocates funding for state program development. In 2010, Congress
passed legislation addressing diabetes prevention through H.R. 3590- the Patient
Protection and Affordable Care Act, SEC. 399V-3- National Diabetes Prevention
Program. The National Diabetes Prevention Program is based on the National Institutes
of Health (NIH) research study and is to establish intervention programs for those at high
risk of developing type 2 diabetes. The program emphasizes improving dietary choices,
increasing physical activity, improving coping skills, and providing group support to help
participants lose 5% to 7% of their body weight and get at least 150 minutes of moderate
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physical activity a week. Thirty-six states in the United States currently have initiated
these programs. There are seven programs available in Nebraska at this time.55
The idea of disease prevention is not new. History tells us that about 400 BC
Hippocrates included the concept of prevention in the Hippocratic Oath “ I will prevent
disease whenever I can, for prevention is preferable to cure”. Now over 2400 years later
we are still searching for answers on how to prevent disease. All of the evidence points
to lifestyle modification, including MNT, as a cost-effective approach to type 2 diabetes
prevention.56 How we accomplish this in different types of clinical or community settings
is yet to determined.
While lifestyle intervention programs in large urban healthcare systems have
proven to be effective in halting or slowing the development of type 2 diabetes, little is
known about how to translate these interventions into practice in rural primary care
clinics where there can be more barriers to health care. Access to programs with
registered dietitian nutritionists and exercise specialists, the professionals qualified to
assist pre-diabetes clients with diet and exercise interventions, is limited in many rural
areas of Nebraska. Distance, time, cost, and the lack of recognized value of MNT may be
factors that impact whether patients receive limited or no MNT intervention for prediabetes.
A notation of change is the American Dietetic Association is now the Academy of
Nutrition and Dietetics and registered dietitians may be referred to as registered dietitian
nutritionists since publication of many of the referenced studies. This research study will
measure the impact of a limited number of MNT sessions provided by a RDN on oneyear outcomes of patients’ with pre-diabetes in a rural primary care clinic in Nebraska.
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The objectives are to: 1) retrospectively collect data from electronic health records (EHR)
of patients newly diagnosed with pre-diabetes in 2010 receiving or not receiving MNT by
a registered dietitian nutritionist in a one year period, 2) examine the data to determine if
a difference is found within or between clinical outcomes of patients receiving or not
receiving MNT, 3) determine if the outcomes are clinically relevant, 4) describe factors
that may impact outcomes, 5) discuss research needed in the future.
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CHAPTER III
METHODOLOGY

Study Design
A quasi-experimental research design was used in this retrospective study to
describe the effect of medical nutrition therapy on patient’s outcomes in a rural Nebraska
primary practice clinic. Electronic health records were reviewed to identify patients
diagnosed with pre-diabetes who were seen for medical care in the clinic in 2010.
Subjects were identified through a computerized search using ICD 9 code 790.29
(abnormal glucose, abnormal non-fasting glucose, hyperglycemia, pre-diabetes) for all
patients seen in the clinic from January to December 2010 by their health-care provider
(HCP). Patients met diagnostic criteria if they had screening fasting plasma glucose of
100-125mg/dl (American Diabetes Association Categories of increased risk for diabetes
(pre-diabetes)). Subjects were assigned to two groups for analysis; those who were
referred by their HCP and received Medical Nutrition Therapy (MNT) (n=20) and those
who did not receive MNT (NMNT) (no MNT referral or MNT referral but the patient did
not seek MNT) (n=22). Deceased patients, pregnant women, those under 18 years of age,
anyone seen for MNT in the past, records with missing diagnostic data, a diagnosis of
abnormal glucose/pre-diabetes but did not meet the American Diabetes Association
diagnostic criteria, and those who had developed type 2 diabetes or were not newly
diagnosed with abnormal glucose/pre-diabetes during 2010 were excluded from the
study.
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MNT was individualized as needed by the RDN to achieve treatment goals using
components of the Academy of Nutrition and Dietetics (AND) MNT Evidence-Based
Nutrition Practice Guidelines for Type 1 and Type 2 Diabetes when counseling patients.
All MNT subjects were advised to alter dietary intake and increase physical activity
(approximately 150 min/week) to achieve a negative energy balance with the goal of 1
pound of weight loss weekly. Sessions included verbal instruction, review of materials,
counseling for behavior modification, motivational interviewing, and goal setting lasting
approximately 1 hour. Exercise recommendations were based on AND guidelines and
the 2008 Physical Activity Guidelines for Adult Americans. A referral to an exercise
specialist was made, as needed.

Data Collection
Baseline weight, height, BMI, FBG, cholesterol, HDL-C, low density lipoprotein
cholesterol (LDL-C), triglycerides, and systolic and diastolic blood pressure at diagnosis
and repeat measurements approximately 12 months from diagnosis as available were
recorded. Also noted were referral from a HCP, any gastrointestinal disturbances (i.e.
GERD, irritable bowel, or Celiac disease), and new medication starts or increased
dosages for hypertension or hyperlipidemia during the year following diagnosis of prediabetes.
Institutional Review Board approval was obtained for the research project from
the University of Nebraska-Lincoln. (Appendix 1) Patient information was kept
confidential by removing names from the database and no other personally identifiable
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information was recorded. Approval was also obtained from the primary care clinic
administrator.
Statistical analysis
Descriptive statistics were used to analyze demographic and clinical information.
Due to the retrospective nature of the study, all data collection points were different
depending on when the patient returned to the clinic for follow up visits after the initial
diagnosis. Due to missing data, actual numbers varied throughout the analysis. Mixed
model analysis was used to adjust for the pattern of variance and covariance and to
account for individual random effects over time. Due to the limited number of time points
(i.e., two times), the compound symmetry variance structure was used. This analysis was
used to examine if condition (MNT/NMNT), time, their interaction, and medications
started or increased can predict the outcomes of interest (i.e., FBG, A1C…). Chi Square
was used to compare observed and expected medicine starts between MNT and NMNT
groups. An alpha level of 0.05 was used to determine statistical significance, although
any trending was considered clinically relevant. Data was analyzed with SAS statistical
software 9.2, 2008.
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CHAPTER IV
RESULTS

Characteristics of the 42 patients meeting criteria for the study are present in
Table 1. Approximately half were seen for MNT by a Registered Dietitian Nutritionist
(RDN) / Certified Diabetes Educator (CDE) for the first time after being newly
diagnosed. The two groups were similar in number (n=22, n= 20), gender mix (female
n=35, 82%, 85%), average age of 62 years old (63 and 61, respectively), and nonHispanic white. Of the patients with available BMI data, a normal BMI (18.5-24.9) was
found in 6% of MNT and 19% of NMNT patients at diagnosis. These patients met
obesity criteria, a BMI greater than 30, in 61% of MNT patients and 44% of NMNT
patients. (Table 6)
Baseline and 1-year clinical data means and standard deviations are shown in
Table 2. There were no significant differences between groups at the initial comparison
other than more subjects were women than men. Results of clinical outcomes after a year
showed weight, BMI, FBG, A1C, total cholesterol and triglyceride decreased and HDL-C
increased in both NMNT and MNT groups. Systolic blood pressure remained stable in
the NMNT group, but decreased in the MNT group. Diastolic blood pressure increased
in both groups. LDL-C decreased in the NMNT group but was stable in the MNT group.
Although clinical changes occurred between the groups none of the changes reached
statistical significance (Table 4) but change was still considered clinically relevant.
Table 3 shows the change within each group from baseline to time 2, approximately one
year later, with corrections for medication starts or increases and estimations of standard
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error. Data analysis showed that both the MNT and NMNT group lost weight. However,
more weight was lost by the MNT group when medication starts or increases were
considered. BMI decreases in the MNT group were double that of the NMNT group
trending toward but not reaching statistical significance. (P=0.12) The MNT group
started with a higher BMI but weighed approximately 12 pounds less than the NMNT
group at diagnosis reflecting taller patients in the NMNT group. The MNT group had a
significantly lower FBG level at approximately 1 year when corrected for medication
changes (P=0.036). When no correction was made for medication, the significance was
even greater (P=0.025). FBG levels were predicted to decrease in both groups. However,
the MNT group was predicted to have an initial FBG 2.28 mg/dL higher than the NMNT
group and was also expected to decrease an additional 4.71mg/dL beyond the NMNT
group. The A1C decrease of 0.22 % points predicted in the MNT group was also
significant (P=0.05) mirroring the decline identified in FBG levels of nearly 7mg/dL
(P=0.036). The MNT group also had significant increases predicted in HDL-C levels of
about 4 mg/dL (P=0.028) while the NMNT group had predicted decreases in
triglycerides of 47 mg/dL (P=0.05). The difference between the NMNT and MNT groups
at baseline and after one year are shown in Table 4. The biggest differences between the
groups were in the parameters with the most significant change within the groups. The
level of change varied with each parameter, however, there were no statistically
significant differences identified between the NMNT and MNT groups for any parameter
after one year.
New prescriptions for patients needing treatment for hypertension or
hyperlipidemia during the year following diagnosis of pre-diabetes are shown in table 5.
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Analysis revealed that the NMNT group had significantly more medication increases or
starts than expected (P=0.01) compared to the MNT group.
HCP referrals for MNT were made in 79% of newly diagnosed cases of prediabetes in 2010. All patients in the MNT group had a HCP referral, as did approximately
55% of the NMNT group. If a referral was made for MNT, it was at the patient’s
discretion to set up the appointment, which happened 48% of the time. Of the patients
seen for MNT, 80% were seen for one visit. Only one person was seen for more than 2
sessions. Patients were seen for an average of 1.2 visits during the year following
diagnosis with a MNT session length of approximately 60 minutes.
Gastrointestinal disorders including irritable bowel syndrome, Celiac disease,
chronic constipation and/or diarrhea and gastroesophageal reflux disease (GERD) were
recorded in 9 (45%) MNT subjects and 12 (55%) NMNT subjects with pre-diabetes.
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CHAPTER V
DISCUSSION

Diabetes is a chronic disease of differing types marked by elevated blood glucose
levels resulting from increased insulin resistance, impaired insulin secretion, or both.
Researchers now recognize that the pancreatic beta cell mass decreases over time leading
to progressive development of the disease. Environmental and genetic factors affect the
onset of type 2 diabetes and can be influenced by lifestyle choices.7 MNT patients were
newly diagnosed by their HCP in 2010, but when insulin resistance began and what
degree of beta cell loss had already occurred is unknown. The initial mean FBG was
higher in the MNT group. This may be due to a later diagnosis or longer duration of
abnormal glucose levels than in the NMNT group, but there was no statistically
significant difference found at baseline between the two groups.
Diabetes is an illness that requires monitoring, ongoing patient education and
support in self-care management of the disease by health-care professionals to help
reduce serious complications and premature death. 2 Registered dietitian nutritionists
(RDN) familiar with components of diabetes MNT play an integral role in intervention
strategies aimed at helping patients prevent the development of diabetes. Individual
sessions with an RDN, as observed in this study, improved patients’ health parameters
that can diminish long-term complications and help prevent the progression to type 2
diabetes. The goal of MNT intervention is not only to control glucose levels but also to
prevent the onset of vascular disease that can be expensive and life threatening. RDNs
providing MNT help patients improve outcomes by normalizing blood pressure and lipid
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levels through diet and exercise. (Appendix 9 and 10) A concern for rural areas is limited
exercise options often exist, especially in inclement weather, which can impact outcomes.
The MNT patients significantly improved their HDL-C; possibly finding ways to
maintain diet and exercise changes over a years’ period of time. The NMNT group had a
significant reduction in triglycerides, but they also had a significant increase in
medication dosages or starts. These medications would be expected to lower elevated
lipid or blood pressure levels, so additions or increases in medication could explain the
significant improvements seen in triglyceride levels of NMNT subjects.
It is unknown why the NMNT group had significantly more medication starts or
increase dosages than the MNT group. Wolf and colleagues concluded in their research
that nutrition intervention by a RDN not only resulted in greater weight loss, better A1C
levels and improved health outcomes, but they also had decreased use of diabetes
prescription medications compared to control groups.40 Sikand and colleagues also
confirmed that 3 hours of RDN intervention over several weeks realized a medication
cost savings for every dollar spent on MNT.53 Because the MNT group had statistically
fewer medication starts or dosage increases, medication side effects and costs would also
be less for this group. If MNT patients followed RDN advice and started regular
exercise, lost weight, and ate healthier it could be expected that need for medications
would decrease or be limited due to improvements in lifestyle.
Preventing negative health outcomes in adults with diabetes can be difficult, as
almost a third do not know they have it. For the same reason it is a bigger challenge to
prevent diabetes in the estimated seventy-nine million adults with pre-diabetes who
typically have no symptoms, no awareness of the disease process or understanding of
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how lifestyle can impact their outcomes. Local, state and national organizations are
working to reduce incidence of diabetes by promoting healthy eating, regular exercise,
and a healthy weight to people at high risk of developing diabetes. The HCPs (physicians
and physician assistants) in this rural Nebraska primary care study referred patients to be
seen by the RDN/CDE for MNT with positive outcomes at one year. Multiple visits with
an RDN were proven successful in improving outcomes in large trials such as the DPP
and DPS. In this study most subjects received only one MNT session over a one-year
period. Current research points to the diminished effect limited visits have on outcomes
over time. Large RCT studies used urban organizations with integrated multidisciplinary intervention programs. Implementation and outcomes in smaller facilities or
communities using American Diabetes Association intervention strategies are now being
studied. There are benefits and concerns that are unique to rural areas, but even in small
clinics, RDNs can provide services that help patients improve health outcomes. The
average patient age in the study was 60 or older where DDP findings show lifestyle
intervention to have the greatest benefit. Researchers confirm that as we age there is a
greater risk for developing diabetes. Aging is also associated with an increase in body
mass and fat deposition. Insulin resistance, a key underlying factor in abnormal glucose
tolerance, is present in individuals who are obese, those with diabetes, and may worsen
with age. Evidence tends to support an association between abdominal obesity and
insulin resistance. Why visceral obesity causes insulin resistance is not clear but may be
related to release of insulin resistant factors from fat cells. It does appear, however, that
insulin resistance is reversed quickly in response to negative energy balance long before
there is reversal of obesity.4 Several studies report that as body weight decreases, insulin
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sensitivity and glucose tolerance improve. Other longitudinal studies indicate regular
aerobic exercise in middle-aged and older adults significantly improve glucose
metabolism. A lower calorie intake and body weight reduction is proven to increase
insulin sensitivity3 Results of this study showed that little weight loss occurred or was
maintained at approximately one year. Greater weight loss was observed in most patients
closer to the time of intervention; however, this data was only observed, not collected and
analyzed. Even though patients had modest weight loss (-2.6 lb.) and BMI change (-0.6)
there were significant improvements in FBG, A1C, and HDL-C. Lifestyle interventions
to promote healthy weight, a nutritious diet and exercise have been shown to improve
insulin sensitivity and bring blood glucose, blood pressure, and lipids to near normal
levels.7 Norris and colleagues concluded that weight loss at modest amounts, even though
not statistically significant, led to improvements in A1C, blood pressure and
triglycerides.18 Researchers from Greece found in the DE-PLAN study that although
weight loss was moderate at about 2 pounds, glucose levels improved in subjects after a
one-year intervention meeting bi-monthly with a RDN. The findings in this MNT
intervention study revealed significant changes within the groups but not between the
groups. Because of limited or no follow up in the MNT group, regression to near the
NMNT group is predictable, as shown in other research findings. This may help explain
why there is no difference seen between the groups. In addition, results may be similar at
a year because of improvements in clinical parameters in the NMNT group after
medication changes or additions. Because of uncontrolled variables, data and time points
missing, correction of data was needed and then showed significant changes within the
MNT group.
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An interesting side note was that gastrointestinal (GI) disorders were documented
in approximately 50% of the pre-diabetes patients. Why GI problems are disturbing half
of the patients studied and if it affects outcomes in this population needs to be studied
further.
Dietary intervention is recommended for individuals with pre-diabetes and should
be provided by a registered dietitian nutritionist who is skilled in MNT for diabetes when
possible. Studies show that multiple individual sessions with a RDN providing MNT
helped patients work for a goal weight loss of at least 7% of initial body weight by
addressing eating behaviors, improving nutritional intake by lowering fat and increasing
fiber intake and developing an exercise plan. Individualized MNT assists patients in
achieving treatment goals and has been shown to improve outcomes with cost savings.
However, pre-diabetes is not a covered diagnosis by most third party payers even though
associations such as the Academy of Nutrition and Dietetics and the American Diabetes
Association recommend MNT be covered by insurance and other payers because of
improved outcomes and cost savings. If a patient is willing or able to pay for services,
diabetes programs and RDNs may not be easily accessible in rural areas due to distance,
cost, and limited or no appointment hours for working people. The patients in this study
all traveled within a 30-mile radius of the facility and paid for the visit expenses. These
could have been limiting factors for some patients and might explain why some did not
seek MNT after an HCP referral or return for follow up sessions. Pre-diabetes patients
generally do not feel ill or have symptoms that affect their daily life. This may be another
reason they do not seek RDN counseling or follow up. The bottom line is that patients are
not getting MNT even though researchers support MNT provided by a RDN over several
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sessions as being highly effective in diabetes prevention. Highly motivated patients are
more likely to participate in clinical trials and take their health-care providers advice in
seeking MNT. Clinical studies show that patients are more likely to seek help with
lifestyle intervention if encouraged by their HCP to do so. Why patients did not attend
MNT sessions after a physician referral is unknown but further study may help in
understanding patient concerns and aid in finding solutions to this problem. It is unknown
why HCPs were not referring for MNT or not consistently documenting referrals for
MNT in the EHR and is an area that could be investigated further. Although HCPs
recognize the impact of diabetes on patients’ health they may not be aware of what an
RDN can do for their patients in preventing diabetes. Further studies on how HCPs view
RDN skills and utilize them may be helpful in positioning RDNs for future roles in
diabetes prevention.
Other questions that need answered concern RDNs accessibility to HCPs and
patients, whether or not adequate positions or RDNs are available to provide the care, and
if the RDN may not be perceived as the expert? Could awareness in the need for
treatment of pre-diabetes by HCPs and the public be low? It is also unknown why
patients in this study chose to receive MNT. They may have been motivated to make
changes for many reasons. More MNT than NMNT subjects were obese which may have
motivated them to seek help in making change. Several studies discuss motivation as a
driving factor in lifestyle modification success. How we reach patients with the greatest
need who are not motivated to change has yet to be discovered.
This study was limited by inconsistent or missing data within MNT and
non-MNT groups due to retrospectively collected information. The small sample size
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impacted the ability to see significance or change that may have occurred so should be
considered a pilot study. The population was predominately females, which tend to visit
their HCP more regularly. Those who chose to complete the MNT referral may have
been more motivated for change, been more affluent, had more flexibility in their
schedule, been more highly educated, and possessed good problem solving skills. There
were no minorities and the age of patients did not include children and young adults.
Single MNT sessions for patients with pre-diabetes were common as patients were
financially responsible for the visit. Because of low return visits this study was unable to
compare the difference that might occur with multiple MNT sessions over time. MNT
provided in an individual session is effective but MNT in a group medical visit format in
rural settings should also be considered. Multiple MNT visits over time with a RDN
leads to more significant outcomes for those with pre-diabetes. Although there is an
initial investment in payments for MNT, cost savings and improved quality of life can be
realized over time and should be researched further.
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CHAPTER VI
CONCLUSIONS

The results of this study suggest that Medical Nutrition Therapy provided by a
Registered Dietitian Nutritionist has a positive effect on clinical outcomes of newly
diagnosed pre-diabetes patients. Despite the small study sample, clinically relevant
changes were observed in BMI and weight among those who received MNT.
Significantly fewer medications starts or increased dosages (P=0.01) were found in those
receiving MNT and a significantly lower FBG (P=0.036) and A1C (P=0.05) along with
improved HDL-C (P=0.03) were observed in patients at approximately one year with
median of 1 visit.
In recent years, evidence from large RCTs have shown the impact of MNT
intervention on delaying the onset of type 2 diabetes in high-risk groups. Most of the
subjects, however, were seen in urban organizations with integrated multi-disciplinary
intervention programs over many visits. Fewer resources for program implementation
and delivery compared to experimental settings may influence results of any type of
intervention in rural primary care. The reality for rural area patients is that nutrition
intervention may not be easily accessible to them. Distance, time, travel, cost, RDN
availability and provider referral may all impact whether a patient is seen for MNT.
Lifestyle change is key to impacting pre-diabetes and this requires continued support,
reassessment, problem solving and goal setting over time. Unfortunately, private
insurance, Medicare and Medicaid do not pay for MNT for pre-diabetes and is likely a
barrier to education and counseling.
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While we need to prove our value and money saving impact through further
randomized clinical controlled trials, registered dietitian nutritionists working in practice
settings can use electronic health records now to conduct chart reviews to measure patient
outcomes. This evidence is needed to support the effect MNT has on clinical outcomes
in people with pre-diabetes. From this information can come changes needed in policy
and reimbursement for MNT.
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Table 1.

Baseline Characteristics of Study Population*
Non MNT group
(n=22)

MNT group
(n=20)

18 (82%)
4 (18%)

17 (85%)
3 (15%)

63 (41-83)

61 (43-86)

202.2 (45.3)

189.7 (27.7)

Height (SD) in.**

67.3 (4.0)

65.3 (3.3)

Body Mass Index, mean (SD)**
Normal
Overweight
Obese

30.8 (6.5)
3 (19%)
6 (38%)
7 (44%)

31.6 (5.1)
1 (6%)
6 (33%)
11(61%)

Race
Caucasian
Other

22 (100%)
0

20 (100%)
0

HCP Referral for MNT ***
Yes
No

13 (59%)
9 (41%)

20 (100%)
0

Gender
Female
Male
Age
Year mean (range)
Weight, mean (SD), lbs.

* No statistically significant differences between groups; ** Data missing; *** Health-care
providers are physicians and physician assistants; MNT- Medical Nutrition Therapy; SD- Standard
Deviation; BMI formula: weight (Kg)/Height (m2)
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Table 2.

Clinical Data of Non MNT and MNT Groups at Baseline and 1 Year

Parameters

NMNT Group
Initial
After 1 year
Mean (SD)
Mean (SD)*

MNT Group
Initial
After 1 year
Mean (SD) Mean (SD)*

Weight (lbs.)

202.2(45.3)

193.8(40.9)

189.70(27.7)

187.3(26.6)

Body mass index **

30.8(6.5)

30.0(5.6)

31.6(5.2)

30.9(4.1)

Fasting blood glucose
(mg/dl)

106.8(9.8)

103.7(13.1)

109.9(6.9)

102.7(12.1)

Hemoglobin A1C (%)

6.1(0.3)

6.0(0.4)

6.2(0.2)

5.8(0.3)

Blood pressure (mmHg)
Systolic
Diastolic

126.5(15.5)
76.2(11.2)

126.3(13.9)
76.7(9.3)

125.9(17.4)
71.4(12.1)

122.8(14.7)
72.9(9.5)

Total cholesterol (mg/dl)

197.5(42.4)

185.8(45.8)

194.4(60.8)

196.7(78.4)

Lipoprotein cholesterol
(mg/dl)
Low density (LDL)
High density (HDL)

109.3(35.7)
52.5(15.9)

105.5(40.0)
54.3(16.7)

110.1(39.9)
50.8(16.5)

110.6(53.1)
51.9(21.6)

Triglycerides (mg/dl)

185.6(124.8)

129.8(56.1)

149.8(95.0)

130.4(86.0)

SD-Standard Deviation; * Data missing, last recorded value close to 12 months; **BMI formula: weight
(Kg)/Height (m2)
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Table 3.

Clinical Changes Within Non MNT and MNT Groups After 1 Year
NMNT group
Difference at
time 2
Mean (SE)

P Value

MNT group
Difference at
time 2
Mean (SE)

P Value

Weight (lbs.)

-2.45(2.67)

0.37

-2.61(2.49)

0.30

Body Mass Index*

-0.35(0.43)

0.42

-0.61(0.38)

0.12

Fasting blood glucose
(mg/dl)

-2.07(2.82)

0.47

-6.78(3.11)

0.036**

Hemoglobin A1C (%)

-0.09(0.07)

0.27

-0.22(0.10)

0.05**

Blood pressure (mmHg)
Systolic
Diastolic

-0.71 (3.92)
-0.26 (2.77)

0.86
0.93

-2.95(3.99)
0.68(2.82)

0.46
0.81

Total cholesterol (mg/dl)

-2.92(8.29)

0.73

-0.54(9.44)

0.96

Lipoprotein cholesterol
(mg/dl)
LDL
HDL

2.84(7.64)
0.31(1.37)

0.71
0.83

1.91(9.44)
3.90(1.65)

0.84
0.028**

-47.17 (22.88)

0.05**

-32.16(27.31)

0.25

Parameter

Triglycerides (mg/dl)

* Data missing, last recorded value close to 12 months; **significant value; SE- Standard Error; BMI
formula: weight (Kg)/Height (m2)
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Table 4.

Difference Between Non MNT and MNT Groups at Baseline and 1 Year

Difference between NMNT and MNT groups
Parameter

Time 1
Mean (SE)

P
Value

Time 2
Mean (SE)

P
Value

Weight (lbs.)

-7.56(13.61)

0.58

-7.72(13.67)

0.58

Body Mass Index*

1.96(2.18)

0.37

1.71(2.18)

0.44

Fasting blood glucose
(mg/dl)

2.28(3.67)

0.54

-2.43(4.12)

0.56

Hemoglobin A1C (%)

-0.04(0.15)

0.78

-0.17(0.15)

0.26

Blood pressure (mmHg)
Systolic
Diastolic

3.53(5.31)
-3.52(3.72)

0.51
0.35

1.28(5.40)
-2.58(3.79)

0.81
0.50

Total cholesterol (mg/dl)

9.13 (20.28)

0.66

11.50 (20.81)

0.58

Lipoprotein cholesterol
(mg/dl)
LDL
HDL

20.55 (13.79)
1.90 (5.39)

0.14
0.73

19.63 (14.31)
5.47(5.46)

0.18
0.32

Triglycerides (mg/dl)

-44.73 (37.58)

0.24

-29.73 (39.98)

0.46

SE- Standard Error; * Data missing, last recorded value close to 12 months; BMI formula: weight
(Kg)/Height (m2)
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Table 5.

Medication Starts or Increases in NMNT and MNT Groups After 1 Year
	
  
NMNT group+

MNT group**

7

0

5

2

9

16

12

2

P value

Medication class
Blood pressure (BP)
Lipids
No new medications for BP,
lipids, or blood glucose
Total starts/increased dose

0.01*

*Due to small sample size chi square may not be valid; **Data missing; + 3 subjects had 2 or more
medication changes or dosage increases; (N)MNT- (non) medical nutrition therapy; BP- blood pressure
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Appendix 1. Institutional Review Board Approval Letter

August 20, 2011
Charlene Dorcey
Department of Nutrition and Health Sciences
103 S Michigan Ave York, NE 68467
Nancy Lewis
Department of Nutrition and Health Sciences
316E LEV, UNL, 68583-0806
IRB Number: 20110811829EP
Project ID: 11829
Project Title: Does Medical Nutrition Therapy affect outcomes in patients with pre-diabetes?
Dear Charlene:
This letter is to officially notify you of the approval of your project by the Institutional Review Board (IRB) for
the Protection of Human Subjects. It is the BoardÂ’s opinion that you have provided adequate safeguards for
the rights and welfare of the participants in this study based on the information provided. Your proposal is in
compliance with this institutionÂ’s Federal Wide Assurance 00002258 and the DHHS Regulations for the
Protection of Human Subjects (45 CFR 46). Your project was approved as an Expedited protocol, category 5.
Date of EP Review: June 30, 2011
You are authorized to implement this study as of the Date of Final Approval: 08/20/2011. This approval is Valid
Until: 08/19/2012.
We wish to remind you that the principal investigator is responsible for reporting to this Board any of the
following events within 48 hours of the event:
* Any serious event (including on-site and off-site adverse events, injuries, side effects, deaths, or other
problems) which in the opinion of the local investigator was unanticipated, involved risk to subjects or others,
and was possibly related to the research procedures;
* Any serious accidental or unintentional change to the IRB-approved protocol that involves risk or has the
potential to recur;
* Any publication in the literature, safety monitoring report, interim result or other finding that indicates an
unexpected change to the risk/benefit ratio of the research;
* Any breach in confidentiality or compromise in data privacy related to the subject or others; or
* Any complaint of a subject that indicates an unanticipated risk or that cannot be resolved by the research staff.
For projects which continue beyond one year from the starting date, the IRB will request continuing review and
update of the research project. Your study will be due for continuing review as indicated above. The investigator
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must also advise the Board when this study is finished or discontinued by completing the enclosed Protocol Final
Report form and returning it to the Institutional Review Board.
If you have any questions, please contact the IRB office at 472-6965.
Sincerely,

William Thomas, Ph.D.
Chair for the IRB
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Appendix 2. American Diabetes Association Testing for Diabetes in Asymptomatic
Patients - Categories of Increased Risk for Diabetes (Prediabetes) *

FPG 100 mg/dL to 125 mg/dL (5.6 mmol/L to 6.9 mmol/L) (IFG)
OR
2-h plasma glucose in the 75-g OGTT 140 mg/dL to 199 mg/dL (7.8 mmol/L to 11.0
mmol/L) (IGT)
OR
A1C 5.7-6.4%
*For all three tests, risk is continuous, extending below the lower limit of the range and
becoming disproportionately greater at higher ends of the range.

American Diabetes Association. Standards of Medical Care in Diabetes-2013. Diabetes
Care. 2013;36(suppl 1): S13. Table 3.
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Appendix 3. American Diabetes Association Classification and Diagnosis of Diabetes
Mellitus	
  -‐	
  Criteria for Diagnosis of Diabetes
	
  

A1C ≥6.5%. The test should be performed in a laboratory using a method that is NGSP
certified and standardized to the DCCT assay. *
OR
FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h. *
OR
2-h plasma glucose ≥200 mg/dL (11.1 mmol/L) during a OGTT. The test should be
performed as described by the WHO, using a glucose load containing the equivalent of
75 g anhydrous glucose dissolved in water. *
OR
In a patient with classic symptoms of hyperglycemia or hyperglycemia crisis, a random
plasma glucose ≥200 mg/dL (11.1 mmol/L).

American Diabetes Association. Standards of Medical Care in Diabetes-2013. Diabetes
Care. 2013;36(suppl 1): S13. Table 2.
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Appendix 4. Diagnostic Criteria for Metabolic Syndrome

Elevated Waist Circumference
• Men: >40 inches
• Women: >35 inches
	
  

Elevated Triglycerides (TG)
• ≥150 mg/dL
or
• Drug treatment for elevated TG
	
  

Reduced HDL-C
• Men: <40 mg/dL
• Women: <50 mg/dL
or
• Drug treatment for reduced HDL-C
	
  

Elevated Blood Pressure
• ≥130 mmHg Systolic BP
or
• ≥85 mmHg Diastolic BP
or
• Drug treatment for hypertension
	
  

Elevated Fasting Plasma Glucose
• ≥100 mg/dL
or
• Drug treatment for elevated glucose

	
  
	
  
	
  
**Any 3 of 5 criteria constitute a diagnosis.	
  

Alberti K, Eckel R, Grundy S, et al. Harmonizing the metabolic syndrome. A Joint
Interim Statement of the International Diabetes Federation Task Force on Epidemiology
and Prevention. National Heart, Lung and Blood Institute; American Heart Association;
World Health Federation; International Atherosclerosis Society; and International
Association for the Study of Obesity. Circulation. 2009; 120:1640-1645.
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Appendix 5. Classification of Overweight and Obesity by Body Mass Index
Classification

BMI

Underweight

<18.5

Normal

18.5-24.9

Overweight

25.0-29.9

Obesity (Class I)

30.0-34.9

Obesity (Class II)

35.0-39.9

Extreme obesity (Class III)

≥40

National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification,
Evaluation and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National
Institutes of Health; 1998.

35

36

37

38

144 151 159 166 174 182 189 197 204 212 219 227 235 242 250 257 265 272 280 288 295 302 310 318 325 333 340 348 355 363 371 378 386 393 401 408
148 155 163 171 179 186 194 202 210 218 225 233 241 249 256 264 272 280 287 295 303 311 319 326 334 342 350 358 365 373 381 389 396 404 412 420
152 160 168 176 184 192 200 208 216 224 232 240 248 256 264 272 279 287 295 303 311 319 327 335 343 351 359 367 375 383 391 399 407 415 423 431
156 164 172 180 189 197 205 213 221 230 238 246 254 263 271 279 287 295 304 312 320 328 336 344 353 361 369 377 385 394 402 410 418 426 435 443

74

75

76

Source: Adapted from Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report.

99 104 109 114 119 124 128 133 138 143 148 153 158 163 168 173 178 183 188 193 198 203 208 212 217 222 227 232 237 242 247 252 257 262 267

140 147 154 162 169 177 184 191 199 206 213 221 228 235 242 250 258 265 272 279 287 294 302 309 316 324 331 338 346 353 361 368 375 383 390 397

54

73

53

136 143 150 157 165 172 179 186 193 200 208 215 222 229 236 243 250 257 265 272 279 286 293 301 308 315 322 329 338 343 351 358 365 372 379 386

52

72

51

132 139 146 153 160 167 174 181 188 195 202 209 216 222 229 236 243 250 257 264 271 278 285 292 299 306 313 320 327 334 341 348 355 362 369 376

50

71

49

128 135 142 149 155 162 169 176 182 189 196 203 209 216 223 230 236 243 250 257 263 270 277 284 291 297 304 311 318 324 331 338 345 351 358 365

48

70

47

69

46

125 131 138 144 151 158 164 171 177 184 190 197 203 210 216 223 230 236 243 249 256 262 269 276 282 289 295 302 308 315 322 328 335 341 348 354

45

121 127 134 140 146 153 159 166 172 178 185 191 198 204 211 217 223 230 236 242 249 255 261 268 274 280 287 293 299 306 312 319 325 331 338 344

44

68

42 43

118 124 130 136 142 148 155 161 167 173 179 186 192 198 204 210 216 223 229 235 241 247 253 260 266 272 278 284 291 297 303 309 315 322 328 334

41

67

40

114 120 126 132 138 144 150 156 162 168 174 180 186 192 198 204 210 216 222 228 234 240 246 252 258 264 270 276 282 288 294 300 306 312 318 324

39

66

Body Weight (pounds)

34

110 116 122 128 134 140 145 151 157 163 169 174 180 186 192 197 204 209 215 221 227 232 238 244 250 256 262 267 273 279 285 291 296 302 308 314

33

65

32

107 113 118 124 130 135 141 146 152 158 163 169 175 180 186 191 197 203 208 214 220 225 231 237 242 248 254 259 265 270 278 282 287 293 299 304

31

64

30

63

29

104 109 115 120 126 131 136 142 147 153 158 164 169 175 180 186 191 196 202 207 213 218 224 229 235 240 246 251 256 262 267 273 278 284 289 295

28

100 106 111 116 122 127 132 137 143 148 153 158 164 169 174 180 185 190 195 201 206 211 217 222 227 232 238 243 248 254 259 264 269 275 280 285

27

62

26

61

25

97 102 107 112 118 123 128 133 138 143 148 153 158 163 168 174 179 184 189 194 199 204 209 215 220 225 230 235 240 245 250 255 261 266 271 276

24

60

23

96 100 105 110 115 119 124 129 134 138 143 148 153 158 162 167 172 177 181 186 191 196 201 205 210 215 220 224 229 234 239 244 248 253 258

22

94

21

Extreme Obesity

91

20

Obese

59

19

Overweight

58

Height
(inches)

BMI

Normal

Body Mass Index Table
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Appendix 6. Body Mass Index Table
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Appendix 7. 2008 Physical Activity Guidelines for Adult Americans
Adults (aged 18–64)
•

2 hours and 30 minutes a week of moderate-intensity physical activity
or

•

1 hour and 15 minutes (75 minutes) a week of vigorous-intensity aerobic physical
activity
or

•

An equivalent combination of moderate- and vigorous-intensity aerobic physical
activity.

•

Aerobic activity should be performed in episodes of at least 10 minutes,
preferably spread throughout the week.

Additional health benefits are provided by increasing to
•

5 hours (300 minutes) a week of moderate-intensity aerobic physical activity
or

•

2 hours and 30 minutes a week of vigorous-intensity physical activity
or

•

An equivalent combination of both.

•

Also do muscle-strengthening activities that involve all major muscle groups
performed on 2 or more days per week.

Older Adults (aged 65 and older)
•

Older adults should follow the adult guidelines.

•

If this is not possible due to limiting chronic conditions, older adults should be as
physically active as their abilities allow.

•

Older adults should avoid inactivity.

•

Older adults should do exercises that maintain or improve balance if they are at
risk of falling.
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Adults with chronic conditions

• Seek the important health benefits from regular physical activity
•

Physical activity only under the guidance of a health care provider.

US Department of Health and Human Services. 2008 Physical Activity Guidelines for
Americans. http://www.health.gov/paguidelines. Accessed March 23, 2013.
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Appendix 8. Correlation of A1C with Mean Plasma Glucose

A1C (%)

Mean Plasma Glucose (mg/dL)

6
7
8
9
10
11
12

126
154
183
212
240
269
298

American Diabetes Association. Standards of Medical Care in Diabetes-2013. Diabetes
Care. 2013;36(suppl 1): S19. Table 8.
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Appendix 9. Classification of Blood Pressure in Adults

Classification

Blood pressure, mmHg

Lifestyle Modification

Normal

SBP* <120
and
DBP+ <80

Encourage

Prehypertension

SBP 120-139
or
DBP 80-89

Yes

Stage 1 hypertension

SBP 140- 159
or
DBP 90- 99

Yes

Stage 2 hypertension

SBP ≥160
or
DBP ≥100

Yes

*Systolic blood pressure; +Diastolic blood pressure
The Seventh Report of the Joint National Committee on Prevention, Detection Evaluation
and Treatment of High Blood Pressure: The JNC 7 Report. Bethesda, MD: National
Institutes of Heart, Lung, and Blood Institute; 2003. NIH publication 03-5231.
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Appendix 10. Classification of Total, LDL, and HDL Cholesterol and Triglycerides

LDL-C
• <70 mg/dL with or high risk for diabetes or overt CVD
• Optimal: <100 mg/dL
• Near or above optimal: 100-129 mg/dL
• Borderline high: 130-159 mg/dL
• High: 160-189 mg/dL
• Very high: ≥190 mg/dL
	
  

Total Cholesterol
• Desirable: <200 mg/dL
• Borderline high: 200-239 mg/dL
• High: ≥240 mg/dL
	
  

HDL-C
• Low: <40 mg/dL in men; <50 mg/dL in women
• High: ≥60 mg/dL
	
  

Triglycerides
• Normal: <150 mg/dL
• Borderline high: 150-199 mg/dL
• High: 200-499 mg/dL
• Very high: ≥500 mg/dL
	
  
	
  

Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Panel III). Bethesda, MD: National Institutes of Health,
National Heart, Lung, and Blood Institute; 2001. NIH publication 01-3670.

